SIGA Stock Risk & Deep Value Analysis
SIGA Technologies Inc
Healthcare • Drug Manufacturers - Specialty & Generic
DVR Score
out of 10
What You Need to Know About SIGA Stock
We analyzed SIGA Technologies Inc using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran SIGA through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Moderate. Here's what we found.
SIGA Risk Analysis & Red Flags
What Could Go Wrong
The primary risk for SIGA is its high dependency on government contracts for TPOXX. A significant reduction in biodefense spending or a decision by major governments not to renew or increase stockpiling could lead to substantial revenue declines and impact profitability.
Risk Matrix
Overall
Moderate
Financial
Low
Market
Medium
Competitive
Low
Execution
Low
Regulatory
Low
Red Flags
- ⚠
High customer concentration (U.S. government as primary buyer)
- ⚠
Reliance on a single primary product (TPOXX)
- ⚠
Limited organic growth drivers outside of existing niche
Upcoming Risk Events
- 📅
Reduction in government biodefense budgets
- 📅
Introduction of a competing smallpox antiviral (low probability, high impact)
When to Reconsider
- 🚪
Loss of a major government contract (e.g., BARDA)
- 🚪
Quarterly revenue falling below $50 million consistently
- 🚪
Significant competitive entry into the smallpox antiviral market
Unlock SIGA Risk Analysis & Red Flags
Create a free account to see the full analysis
What Does SIGA Technologies Inc (SIGA) Do?
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
46
SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security market in the United States. Its lead product is TPOXX, an antiviral drug for the treatment of human smallpox disease caused by variola virus. The company was incorporated in 1995 and is headquartered in New York, New York.
Visit SIGA Technologies Inc WebsiteInvestment Thesis
SIGA Technologies offers a stable, profitable investment opportunity within the biodefense sector, driven by its monopolistic position with TPOXX and consistent government contracts. While lacking significant 10x growth potential, it provides robust financial health and potential for consistent returns through dividends or incremental international expansion.
Is SIGA Stock Undervalued?
Unlock the full AI analysis for SIGA
Get the complete DVR score, risk analysis, and more
Unlock the full report
Create a free account to see the DVR score, risk flags, and AI analysis.
SIGA Price Targets & Strategy
12-Month Target
$6.50
Bull Case
$8.00
Bear Case
$4.50
Valuation Basis
Based on 8x forward P/E applied to estimated FY26 EPS of $0.81 (reflecting stable biodefense contracts) = $6.48, rounded to $6.50.
Entry Strategy
Consider dollar-cost averaging between $5.00-$5.30 (around current levels, monitoring for dips towards recent support).
Exit Strategy
Take profit at $7.50-$8.00; Stop loss at $4.40 (below critical support).
Portfolio Allocation
1-3% for moderate risk tolerance (conservative portfolio seeking stable, non-cyclical exposure).
Price Targets & Strategy
Upgrade to Premium for price targets and entry/exit strategies
Does SIGA Have a Competitive Moat?
Sign in to unlockMoat Rating
🛡️ Narrow
Moat Trend
Stable
Moat Sources
3 Identified
The moat is durable due to TPOXX's FDA approval for smallpox, making it a critical asset for government biodefense stockpiles. The regulatory hurdles and cost for a competitor to replicate this position are substantial, ensuring TPOXX's continued relevance for its intended use.
Moat Erosion Risks
- •Government budget cuts or shifts in biodefense priorities
- •Expiry of key patents without new product development
- •Emergence of a superior, broadly effective antiviral
SIGA Competitive Moat Analysis
Sign up to see competitive advantages
SIGA Market Intelligence
Sentiment & Insider Activity
Social Sentiment
Neutral - Niche company with limited mainstream retail investor chatter, focus tends to be on stability and dividends rather than growth.
Institutional Sentiment
Neutral - Analysts typically cover it for its stability rather than explosive growth. Recent activity likely stable with no significant upgrades/downgrades.
Insider Activity (Form 4)
Normal insider activity, no significant buys/sells reported recently that would indicate a major shift in sentiment.
Options Flow
Normal options activity; put/call ratio likely stable, not indicating unusual institutional positioning.
Earnings Intelligence
Next Earnings
Estimated early May 2026
Surprise Probability
Low - Due to the nature of government contracts, earnings tend to be predictable, though contract timing can cause lumpiness.
Historical Earnings Pattern
Tends to be relatively stable post-earnings, with reactions largely tied to contract announcements or updated guidance rather than typical beats/misses.
Key Metrics to Watch
Competitive Position
Top Competitor
EMER
Market Share Trend
Stable - Dominant in its specific niche (smallpox antiviral stockpiling).
Valuation vs Peers
Trading at a discount on a P/E basis compared to high-growth biotech peers, but in line with or at a slight premium to other stable government contractors in the biodefense space due to its unique product positioning.
Competitive Advantages
- •Proprietary FDA-approved smallpox antiviral (TPOXX)
- •Established government contracts and relationships (BARDA)
- •High barrier to entry for new competitors in biodefense
Market Intelligence
Get sentiment, earnings intel, and peer analysis with Premium
What Could Drive SIGA Stock Higher?
Near-Term (0-6 months)
- •Q1 2026 Earnings Report (estimated late April 2026)
- •Potential new international procurement orders for TPOXX
Medium-Term (6-18 months)
- •Expansion of TPOXX into additional indications (e.g., mpox stockpiling)
- •Long-term contract renewals or significant increases in US government orders (BARDA)
Long-Term (18+ months)
- •Global biodefense market growth due to emerging threats
- •Successful development and commercialization of a new product beyond TPOXX
Catalysts & Growth Drivers
Upgrade to Premium to see catalysts
What's the Bull Case for SIGA?
- ✓
Significant new international TPOXX procurement announcements
- ✓
Progress on new indications or product development pipeline
- ✓
Consistent dividend increases (if initiated or expanded)
Bull Case Analysis
See what could go right with Premium
Competing with SIGA
See how SIGA Technologies Inc compares to related companies
| Company | Market Cap | DVR Score | P/E | Revenue | Profit Margin | Rev Growth | |
|---|---|---|---|---|---|---|---|
SIGA Technologies Inc SIGA | — | 3.8 | — | — | — | — | |
AbbVie Inc ABBV | $403.8B | 0.1 | 171.8 | — | — | — | Compare → |
Johnson & Johnson JNJ | — | 1.0 | — | — | — | — | Compare → |
Pfizer Inc PFE | $150.6B | 0.2 | 19.4 | $62.6B | 12.4% | -1.6% | Compare → |
UnitedHealth Group Inc UNH | $276.2B | 0.3 | 22.9 | $113.7B | 2.7% | 1181.0% | Compare → |
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.
FAQ
What is the DVR Score for SIGA Technologies Inc (SIGA)?
As of March 30, 2026, SIGA Technologies Inc has a DVR Score of 3.8 out of 10, placing it in the "Risk Trap" category. This score is generated by our AI-powered deep value analysis framework that evaluates growth potential, financial health, competitive moat, and risk factors.
What ticker symbol does SIGA Technologies Inc use?
SIGA is the ticker symbol for SIGA Technologies Inc. The company trades on the NGM.
What is the risk level for SIGA stock?
Our analysis rates SIGA Technologies Inc's overall risk as Moderate. This assessment considers execution risk, market risk, financial risk, competitive risk, and regulatory risk. For a full breakdown, see the risk analysis section above.
How often is the SIGA DVR analysis updated?
Our AI-powered analysis of SIGA Technologies Inc is refreshed regularly to incorporate the latest financial data, market conditions, and news. The most recent update was on March 30, 2026.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for SIGA (SIGA Technologies Inc) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.